

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information  
Full Analysis Dataset : HUNGARY**

Number of prospective patients (C1+C2+C3+C4+C5 )	1361
Number of enrolling sites	23
Number of enrolling countries	1
Enrolment period	30JUL2012 - 26JUL2016
Duration of enrolment (months)	47.9

**Table 02: Patients by region, country, and cohort  
Full Analysis Dataset : HUNGARY**

<b>Region</b>	<b>Country</b>	<b>Cohort 2 (N=339)</b>	<b>Cohort 3 (N=364)</b>	<b>Cohort 4 (N=306)</b>	<b>Cohort 5 (N=352)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=1361)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=1009)</b>
Europe	Hungary	339	364	306	352	1361	1009

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Sex, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Male	173 (51.0)	168 (46.2)	144 (47.1)	174 (49.4)	659 (48.4)	485 (48.1)
	Female	166 (49.0)	196 (53.8)	162 (52.9)	178 (50.6)	702 (51.6)	524 (51.9)
Age at Diagnosis (Years)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Mean (SD)	68.2 (10.2)	68.9 (10.5)	68.7 (9.8)	68.4 (10.5)	68.6 (10.3)	68.6 (10.2)
	Median (IQR)	69.0 (61.0 to 76.0)	70.0 (62.0 to 77.0)	70.0 (62.0 to 76.0)	69.0 (62.0 to 75.0)	69.0 (62.0 to 76.0)	69.0 (62.0 to 76.0)
	Min to Max	26 to 90	38 to 93	36 to 95	31 to 96	26 to 96	26 to 95
Age Group, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	<65	112 (33.0)	116 (31.9)	98 (32.0)	115 (32.7)	441 (32.4)	326 (32.3)
	65-74	129 (38.1)	124 (34.1)	121 (39.5)	136 (38.6)	510 (37.5)	374 (37.1)
	>=75	98 (28.9)	124 (34.1)	87 (28.4)	101 (28.7)	410 (30.1)	309 (30.6)
Time since AF Diagnosis (Weeks)	n (missing)	236 (103)	285 (79)	250 (56)	314 (38)	1085 (276)	771 (238)
	Mean (SD)	1.63 (1.60)	1.42 (1.40)	1.47 (1.46)	1.18 (1.21)	1.41 (1.42)	1.50 (1.48)
	Median (IQR)	1.00 (0.40 to 2.40)	1.00 (0.50 to 1.80)	1.00 (0.50 to 1.80)	0.80 (0.40 to 1.40)	1.00 (0.40 to 1.80)	1.00 (0.40 to 2.00)
	Min to Max	0.1 to 6.0	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Caucasian	338 (99.7)	362 (99.5)	306 (100.0)	352 (100.0)	1358 (99.8)	1006 (99.7)
	Hispanic/Latino	1 (0.3)	1 (0.3)	-	-	2 (0.1)	2 (0.2)
	Mixed/Other	-	1 (0.3)	-	-	1 (0.1)	1 (0.1)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : HUNGARY**

<b>Variable</b>	<b>Statistics</b>	<b>Cohort 2 (N=339) (n %)</b>	<b>Cohort 3 (N=364) (n %)</b>	<b>Cohort 4 (N=306) (n %)</b>	<b>Cohort 5 (N=352) (n %)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=1361)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=1009)</b>
Region, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Europe	339 (100.0)	364 (100.0)	306 (100.0)	352 (100.0)	1361 (100.0)	1009 (100.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Care Setting	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
Speciality at Diagnosis, n(%)							
	Internal Medicine	83 (24.5)	74 (20.3)	83 (27.1)	75 (21.3)	315 (23.1)	240 (23.8)
	Cardiology	195 (57.5)	225 (61.8)	200 (65.4)	262 (74.4)	882 (64.8)	620 (61.4)
	Neurology	5 (1.5)	3 (0.8)	2 (0.7)	1 (0.3)	11 (0.8)	10 (1.0)
	Primary Care/General Practice	56 (16.5)	62 (17.0)	21 (6.9)	14 (4.0)	153 (11.2)	139 (13.8)
Care Setting	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
Location at Diagnosis, n(%)							
	Hospital	228 (67.3)	212 (58.2)	198 (64.7)	251 (71.3)	889 (65.3)	638 (63.2)
	Office	57 (16.8)	62 (17.0)	42 (13.7)	61 (17.3)	222 (16.3)	161 (16.0)
	Anticoagulation clinic/thrombosi s centre	-	1 (0.3)	3 (1.0)	2 (0.6)	6 (0.4)	4 (0.4)
	Emergency room	54 (15.9)	89 (24.5)	63 (20.6)	38 (10.8)	244 (17.9)	206 (20.4)
Type of AF Diagnosed, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Permanent	48 (14.2)	56 (15.4)	34 (11.1)	44 (12.5)	182 (13.4)	138 (13.7)
	Persistent	44 (13.0)	29 (8.0)	36 (11.8)	53 (15.1)	162 (11.9)	109 (10.8)
	Paroxysmal	90 (26.5)	100 (27.5)	78 (25.5)	106 (30.1)	374 (27.5)	268 (26.6)
	New	157 (46.3)	179 (49.2)	158 (51.6)	149 (42.3)	643 (47.2)	494 (49.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Treatment Costs, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	Public insurance	300 (88.5)	348 (95.6)	302 (98.7)	339 (96.3)	1289 (94.7)	950 (94.2)
	Private (insurance)	10 (2.9)	2 (0.5)	-	1 (0.3)	13 (1.0)	12 (1.2)
	Private (out of pocket)	-	1 (0.3)	-	-	1 (0.1)	1 (0.1)
	Combination	29 (8.6)	13 (3.6)	4 (1.3)	12 (3.4)	58 (4.3)	46 (4.6)
Treatment Sector, n(%)	n (missing)	337 (0)	364 (0)	306 (0)	352 (0)	1359 (0)	1007 (0)
	In the public sector	301 (89.3)	353 (97.0)	301 (98.4)	349 (99.1)	1304 (96.0)	955 (94.8)
	In the private sector	36 (10.7)	11 (3.0)	5 (1.6)	3 (0.9)	55 (4.0)	52 (5.2)
	Unknown	2	-	-	-	2	2



**Table 05 : Vital signs and life style  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Height (cm)	n (missing)	254 (85)	262 (102)	237 (69)	270 (82)	1023 (338)	753 (256)
	Mean (SD)	168.6 (9.1)	168.0 (9.3)	168.2 (8.7)	169.4 (8.9)	168.6 (9.0)	168.3 (9.1)
	Median (IQR)	168.0 (163.0 to 175.0)	168.0 (161.0 to 175.0)	168.0 (162.0 to 175.0)	168.0 (163.0 to 175.0)	168.0 (162.0 to 175.0)	168.0 (162.0 to 175.0)
	Min to Max	143 to 206	148 to 194	145 to 190	147 to 204	143 to 206	143 to 206
Weight (kg)	n (missing)	254 (85)	262 (102)	237 (69)	270 (82)	1023 (338)	753 (256)
	Mean (SD)	83.8 (18.7)	82.5 (19.6)	82.9 (18.9)	85.0 (18.2)	83.6 (18.8)	83.0 (19.0)
	Median (IQR)	81.0 (72.0 to 93.0)	80.0 (69.0 to 94.0)	82.0 (70.0 to 92.0)	84.0 (72.0 to 95.0)	82.0 (70.0 to 94.0)	81.0 (70.0 to 93.0)
	Min to Max	48 to 150	36 to 150	37 to 145	47 to 156	36 to 156	36 to 150
BMI (kg/m <sup>2</sup> )	n (missing)	254 (85)	262 (102)	237 (69)	270 (82)	1023 (338)	753 (256)
	Mean (SD)	29.4 (5.5)	29.1 (5.9)	29.3 (5.8)	29.6 (5.8)	29.3 (5.8)	29.2 (5.7)
	Median (IQR)	29.0 (26.0 to 32.0)	28.0 (24.0 to 33.0)	28.0 (25.0 to 33.0)	29.0 (26.0 to 32.0)	28.0 (25.0 to 33.0)	28.0 (25.0 to 33.0)
	Min to Max	17 to 49	15 to 54	17 to 49	17 to 52	15 to 54	15 to 54
BMI Category, n(%)	n (missing)	254 (85)	262 (102)	237 (69)	270 (82)	1023 (338)	753 (256)
	<19	3 (1.2)	4 (1.5)	5 (2.1)	4 (1.5)	16 (1.6)	12 (1.6)
	19-<25	45 (17.7)	75 (28.6)	54 (22.8)	49 (18.1)	223 (21.8)	174 (23.1)
	25-<30	108 (42.5)	76 (29.0)	87 (36.7)	108 (40.0)	379 (37.0)	271 (36.0)
	30-<40	86 (33.9)	90 (34.4)	80 (33.8)	93 (34.4)	349 (34.1)	256 (34.0)
	>=40	12 (4.7)	17 (6.5)	11 (4.6)	16 (5.9)	56 (5.5)	40 (5.3)
Pulse (bpm)	n (missing)	332 (7)	361 (3)	303 (3)	345 (7)	1341 (20)	996 (13)
	Mean (SD)	98.4 (28.3)	100.9 (30.1)	99.3 (27.5)	100.2 (29.0)	99.7 (28.8)	99.6 (28.7)
	Median (IQR)	91.5 (74.5 to 120.0)	95.0 (76.0 to 122.0)	96.0 (80.0 to 120.0)	100.0 (78.0 to 120.0)	96.0 (76.0 to 120.0)	95.0 (76.0 to 120.0)
	Min to Max	48 to 170	42 to 227	35 to 180	41 to 183	35 to 227	35 to 227

**Table 05 : Vital signs and life style  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Systolic BP (mm Hg)	n (missing)	327 (12)	361 (3)	304 (2)	347 (5)	1339 (22)	992 (17)
	Mean (SD)	133.1 (16.2)	133.8 (18.2)	133.2 (17.8)	134.6 (19.1)	133.7 (17.9)	133.4 (17.4)
	Median (IQR)	133.0 (120.0 to 144.0)	133.0 (120.0 to 144.0)	130.0 (120.0 to 142.0)	130.0 (120.0 to 145.0)	130.0 (120.0 to 144.0)	131.5 (120.0 to 142.5)
	Min to Max	87 to 180	89 to 210	90 to 200	90 to 196	87 to 210	87 to 210
Diastolic BP (mm Hg)	n (missing)	327 (12)	361 (3)	304 (2)	347 (5)	1339 (22)	992 (17)
	Mean (SD)	81.2 (11.0)	81.8 (11.1)	81.0 (10.8)	81.3 (11.4)	81.3 (11.1)	81.3 (11.0)
	Median (IQR)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (74.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)
	Min to Max	50 to 125	50 to 118	46 to 130	53 to 112	46 to 130	46 to 130
LVEF (%)	n (missing)	281 (58)	295 (69)	256 (50)	291 (61)	1123 (238)	832 (177)
	Mean (SD)	55.2 (10.5)	55.5 (12.0)	56.7 (12.3)	56.6 (11.1)	56.0 (11.5)	55.8 (11.6)
	Median (IQR)	56.0 (50.0 to 62.0)	58.0 (50.0 to 64.0)	58.0 (50.0 to 64.0)	59.0 (51.0 to 64.0)	58.0 (50.0 to 64.0)	57.5 (50.0 to 63.0)
	Min to Max	20 to 80	20 to 77	15 to 91	19 to 84	15 to 91	15 to 91
LVEF Category, n (missing) n(%)	n (missing)	281 (58)	295 (69)	256 (50)	291 (61)	1123 (238)	832 (177)
	<40%	23 (8.2)	32 (10.8)	22 (8.6)	28 (9.6)	105 (9.3)	77 (9.3)
	>=40%	258 (91.8)	263 (89.2)	234 (91.4)	263 (90.4)	1018 (90.7)	755 (90.7)
History of Hypertension, n(%)	n (missing)	339 (0)	363 (0)	306 (0)	351 (0)	1359 (0)	1008 (0)
	No	26 (7.7)	37 (10.2)	39 (12.7)	31 (8.8)	133 (9.8)	102 (10.1)
	Yes	313 (92.3)	326 (89.8)	267 (87.3)	320 (91.2)	1226 (90.2)	906 (89.9)

**Table 05 : Vital signs and life style  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
	Unknown	-	1	-	1	2	1
Alcohol Consumption, n(%)	n (missing)	306 (0)	346 (0)	271 (0)	315 (0)	1238 (0)	923 (0)
	Abstinent	203 (66.3)	219 (63.3)	167 (61.6)	184 (58.4)	773 (62.4)	589 (63.8)
	Light	83 (27.1)	103 (29.8)	84 (31.0)	97 (30.8)	367 (29.6)	270 (29.3)
	Moderate	16 (5.2)	21 (6.1)	18 (6.6)	30 (9.5)	85 (6.9)	55 (6.0)
	Heavy	4 (1.3)	3 (0.9)	2 (0.7)	4 (1.3)	13 (1.1)	9 (1.0)
	Unknown	33	18	35	37	123	86
Smoker, n(%)	n (missing)	307 (0)	344 (0)	264 (0)	316 (0)	1231 (0)	915 (0)
	No	235 (76.5)	249 (72.4)	207 (78.4)	218 (69.0)	909 (73.8)	691 (75.5)
	Ex-smoker	47 (15.3)	59 (17.2)	36 (13.6)	63 (19.9)	205 (16.7)	142 (15.5)
	Current smoker	25 (8.1)	36 (10.5)	21 (8.0)	35 (11.1)	117 (9.5)	82 (9.0)
	Unknown	32	20	42	36	130	94

**Table 06 : Clinical History**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Congestive heart failure, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	298 (87.9)	273 (75.0)	246 (80.4)	279 (79.3)	1096 (80.5)	817 (81.0)
	Yes	41 (12.1)	91 (25.0)	60 (19.6)	73 (20.7)	265 (19.5)	192 (19.0)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	41 (298)	87 (273)	56 (246)	60 (279)	244 (1096)	184 (817)
	I	6 (14.6)	25 (28.7)	5 (8.9)	14 (23.3)	50 (20.5)	36 (19.6)
	II	22 (53.7)	34 (39.1)	26 (46.4)	27 (45.0)	109 (44.7)	82 (44.6)
	III	10 (24.4)	23 (26.4)	17 (30.4)	12 (20.0)	62 (25.4)	50 (27.2)
	IV	3 (7.3)	5 (5.7)	8 (14.3)	7 (11.7)	23 (9.4)	16 (8.7)
	Unknown	-	4	4	13	21	8
Coronary artery disease, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	268 (79.1)	265 (72.8)	237 (77.5)	274 (77.8)	1044 (76.7)	770 (76.3)
	Yes	71 (20.9)	99 (27.2)	69 (22.5)	78 (22.2)	317 (23.3)	239 (23.7)
Acute coronary syndrome, n(%)	n (missing)	339 (0)	360 (0)	305 (0)	351 (0)	1355 (0)	1004 (0)
	No	312 (92.0)	327 (90.8)	280 (91.8)	320 (91.2)	1239 (91.4)	919 (91.5)
	Yes	27 (8.0)	33 (9.2)	25 (8.2)	31 (8.8)	116 (8.6)	85 (8.5)
	Unknown	-	4	1	1	6	5
Carotid Occlusive Disease, n(%)	n (missing)	339 (0)	356 (0)	302 (0)	346 (0)	1343 (0)	997 (0)
	No	330 (97.3)	336 (94.4)	292 (96.7)	325 (93.9)	1283 (95.5)	958 (96.1)

**Table 06 : Clinical History**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
	Yes	9 (2.7)	20 (5.6)	10 (3.3)	21 (6.1)	60 (4.5)	39 (3.9)
	Unknown	-	8	4	6	18	12
PE or DVT, n(%)	n (missing)	339 (0)	362 (0)	305 (0)	351 (0)	1357 (0)	1006 (0)
	No	327 (96.5)	335 (92.5)	288 (94.4)	333 (94.9)	1283 (94.5)	950 (94.4)
	Yes	12 (3.5)	27 (7.5)	17 (5.6)	18 (5.1)	74 (5.5)	56 (5.6)
	Unknown	-	2	1	1	4	3
Other Thromboemboli sm, n(%)	n (missing)	335 (4)	0 (364)	0 (306)	0 (352)	335 (1026)	335 (674)
	No	333 (99.4)	-	-	-	333 (99.4)	333 (99.4)
	Yes	2 (0.6)	-	-	-	2 (0.6)	2 (0.6)
Systemic Embolization, n(%)	n (missing)	339 (0)	359 (0)	304 (0)	351 (0)	1353 (0)	1002 (0)
	No	336 (99.1)	358 (99.7)	301 (99.0)	348 (99.1)	1343 (99.3)	995 (99.3)
	Yes	3 (0.9)	1 (0.3)	3 (1.0)	3 (0.9)	10 (0.7)	7 (0.7)
	Unknown	-	5	2	1	8	7
Coronary Artery Bypass Graft, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	351 (0)	1360 (0)	1009 (0)
	No	325 (95.9)	351 (96.4)	298 (97.4)	339 (96.6)	1313 (96.5)	974 (96.5)
	Yes	14 (4.1)	13 (3.6)	8 (2.6)	12 (3.4)	47 (3.5)	35 (3.5)
	Unknown	-	-	-	1	1	-
Stroke/TIA, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)

**Table 06 : Clinical History**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
	No	294 (86.7)	321 (88.2)	278 (90.8)	316 (89.8)	1209 (88.8)	893 (88.5)
	Yes	45 (13.3)	43 (11.8)	28 (9.2)	36 (10.2)	152 (11.2)	116 (11.5)
Stroke, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	351 (0)	1360 (0)	1009 (0)
	No	311 (91.7)	338 (92.9)	290 (94.8)	334 (95.2)	1273 (93.6)	939 (93.1)
	Yes	28 (8.3)	26 (7.1)	16 (5.2)	17 (4.8)	87 (6.4)	70 (6.9)
	Unknown	-	-	-	1	1	-
History of Bleeding, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	325 (95.9)	352 (96.7)	303 (99.0)	341 (96.9)	1321 (97.1)	980 (97.1)
	Yes	14 (4.1)	12 (3.3)	3 (1.0)	11 (3.1)	40 (2.9)	29 (2.9)
Hypercholester olaemia, n(%)	n (missing)	339 (0)	355 (0)	301 (0)	346 (0)	1341 (0)	995 (0)
	No	140 (41.3)	167 (47.0)	148 (49.2)	171 (49.4)	626 (46.7)	455 (45.7)
	Yes	199 (58.7)	188 (53.0)	153 (50.8)	175 (50.6)	715 (53.3)	540 (54.3)
	Unknown	-	9	5	6	20	14
Diabetes, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	219 (64.6)	277 (76.1)	227 (74.2)	243 (69.0)	966 (71.0)	723 (71.7)
	Type I	2 (0.6)	2 (0.5)	4 (1.3)	4 (1.1)	12 (0.9)	8 (0.8)
	Type II	118 (34.8)	85 (23.4)	75 (24.5)	105 (29.8)	383 (28.1)	278 (27.6)
Diabetes, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	219 (64.6)	277 (76.1)	227 (74.2)	243 (69.0)	966 (71.0)	723 (71.7)
	Yes	120 (35.4)	87 (23.9)	79 (25.8)	109 (31.0)	395 (29.0)	286 (28.3)
Cirrhosis, n(%)	n (missing)	339 (0)	359 (0)	305 (0)	350 (0)	1353 (0)	1003 (0)
	No	335 (98.8)	357 (99.4)	303 (99.3)	342 (97.7)	1337 (98.8)	995 (99.2)
	Yes	4 (1.2)	2 (0.6)	2 (0.7)	8 (2.3)	16 (1.2)	8 (0.8)

**Table 06 : Clinical History**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
	Unknown	-	5	1	2	8	6
Dementia, n(%)	n (missing)	339 (0)	363 (0)	306 (0)	350 (0)	1358 (0)	1008 (0)
	No	334 (98.5)	354 (97.5)	305 (99.7)	345 (98.6)	1338 (98.5)	993 (98.5)
	Yes	5 (1.5)	9 (2.5)	1 (0.3)	5 (1.4)	20 (1.5)	15 (1.5)
	Unknown	-	1	-	2	3	1
Hyperthyroidism, n(%)	n (missing)	339 (0)	363 (0)	305 (0)	350 (0)	1357 (0)	1007 (0)
	No	335 (98.8)	355 (97.8)	299 (98.0)	344 (98.3)	1333 (98.2)	989 (98.2)
	Yes	4 (1.2)	8 (2.2)	6 (2.0)	6 (1.7)	24 (1.8)	18 (1.8)
	Unknown	-	1	1	2	4	2
Hypothyroidism, n(%)	n (missing)	339 (0)	363 (0)	304 (0)	350 (0)	1356 (0)	1006 (0)
	No	312 (92.0)	342 (94.2)	294 (96.7)	328 (93.7)	1276 (94.1)	948 (94.2)
	Yes	27 (8.0)	21 (5.8)	10 (3.3)	22 (6.3)	80 (5.9)	58 (5.8)
	Unknown	-	1	2	2	5	3
Vascular Disease, n(%)	n (missing)	339 (0)	363 (1)	304 (2)	351 (1)	1357 (4)	1006 (3)
	No	291 (85.8)	304 (83.7)	262 (86.2)	296 (84.3)	1153 (85.0)	857 (85.2)
	Yes	48 (14.2)	59 (16.3)	42 (13.8)	55 (15.7)	204 (15.0)	149 (14.8)
Moderate to Severe CKD, n(%)	n (missing)	339 (0)	364 (0)	306 (0)	352 (0)	1361 (0)	1009 (0)
	No	296 (87.3)	307 (84.3)	271 (88.6)	305 (86.6)	1179 (86.6)	874 (86.6)
	Yes	43 (12.7)	57 (15.7)	35 (11.4)	47 (13.4)	182 (13.4)	135 (13.4)

**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
Baseline Treatment, n(%)	n (missing)	329 (0)	346 (0)	302 (0)	352 (0)	1329 (0)	977 (0)
	VKA	154 (46.8)	167 (48.3)	173 (57.3)	195 (55.4)	689 (51.8)	494 (50.6)
	VKA+AP	60 (18.2)	64 (18.5)	49 (16.2)	58 (16.5)	231 (17.4)	173 (17.7)
	FXA	11 (3.3)	13 (3.8)	13 (4.3)	15 (4.3)	52 (3.9)	37 (3.8)
	FXA+AP	5 (1.5)	10 (2.9)	3 (1.0)	5 (1.4)	23 (1.7)	18 (1.8)
	DTI	17 (5.2)	30 (8.7)	9 (3.0)	17 (4.8)	73 (5.5)	56 (5.7)
	DTI+AP	11 (3.3)	6 (1.7)	3 (1.0)	3 (0.9)	23 (1.7)	20 (2.0)
	AP	37 (11.2)	25 (7.2)	30 (9.9)	30 (8.5)	122 (9.2)	92 (9.4)
	NONE	34 (10.3)	31 (9.0)	22 (7.3)	29 (8.2)	116 (8.7)	87 (8.9)
	Unknown	10	18	4	-	32	32
	VKA±AP	214 (65.0)	231 (66.8)	222 (73.5)	253 (71.9)	920 (69.2)	667 (68.3)
	FXA±AP	16 (4.9)	23 (6.6)	16 (5.3)	20 (5.7)	75 (5.6)	55 (5.6)
	DTI±AP	28 (8.5)	36 (10.4)	12 (4.0)	20 (5.7)	96 (7.2)	76 (7.8)
	FXA/DTI	28 (8.5)	43 (12.4)	22 (7.3)	32 (9.1)	125 (9.4)	93 (9.5)
	FXA/DTI+AP	16 (4.9)	16 (4.6)	6 (2.0)	8 (2.3)	46 (3.5)	38 (3.9)
	FXA/DTI±AP	44 (13.4)	59 (17.1)	28 (9.3)	40 (11.4)	171 (12.9)	131 (13.4)
	AC	182 (55.3)	210 (60.7)	195 (64.6)	227 (64.5)	814 (61.2)	587 (60.1)
	AC+AP	76 (23.1)	80 (23.1)	55 (18.2)	66 (18.8)	277 (20.8)	211 (21.6)
	AC±AP	258 (78.4)	290 (83.8)	250 (82.8)	293 (83.2)	1091 (82.1)	798 (81.7)



**Table 08: Treatment**  
**Full Analysis Dataset : HUNGARY**

	<b>Cohort 2</b> <b>(N=339)</b> <b>(n %)</b>	<b>Cohort 3</b> <b>(N=364)</b> <b>(n %)</b>	<b>Cohort 4</b> <b>(N=306)</b> <b>(n %)</b>	<b>Cohort 5</b> <b>(N=352)</b> <b>(n %)</b>	<b>Total</b> <b>Prospective</b> <b>patients</b> <b>Cohorts 1 to 5</b> <b>(N=1361)</b>	<b>Total</b> <b>Prospective</b> <b>patients</b> <b>Cohorts 1 to 4</b> <b>(N=1009)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>						
ADP receptor/P2Y12 inhibitors	34 (10.0)	39 (10.7)	25 (8.2)	30 (8.5)	128 (9.4)	98 (9.7)
Prostaglandin Cox inhibitors	-	-	-	2 (0.6)	2 (0.1)	
ASA	-	7 (1.9)	3 (1.0)	1 (0.3)	11 (0.8)	10 (1.0)
	92 (27.1)	79 (21.7)	66 (21.6)	74 (21.0)	311 (22.9)	237 (23.5)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>						
VKA	222 (65.5)	245 (67.3)	225 (73.5)	253 (71.9)	945 (69.4)	692 (68.6)
FXa	24 (7.1)	41 (11.3)	19 (6.2)	20 (5.7)	104 (7.6)	84 (8.3)
DTI	28 (8.3)	40 (11.0)	12 (3.9)	20 (5.7)	100 (7.3)	80 (7.9)
Heparinoid	2 (0.6)	6 (1.6)	-	-	8 (0.6)	8 (0.8)
Heparins	87 (25.7)	56 (15.4)	39 (12.7)	41 (11.6)	223 (16.4)	182 (18.0)
Other	2 (0.6)	2 (0.5)	-	1 (0.3)	5 (0.4)	4 (0.4)

**Table 09 : Risk scores**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
CHADS2 Score	n (missing)	339 (0)	362 (2)	306 (0)	351 (1)	1358 (3)	1007 (2)
	Mean (SD)	2.0 (1.1)	2.0 (1.1)	1.8 (1.1)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 6	0 to 5	0 to 6	0 to 5	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	339 (0)	362 (2)	306 (0)	351 (1)	1358 (3)	1007 (2)
	0	6 (1.8)	16 (4.4)	18 (5.9)	15 (4.3)	55 (4.1)	40 (4.0)
	1	117 (34.5)	119 (32.9)	129 (42.2)	120 (34.2)	485 (35.7)	365 (36.2)
	2	129 (38.1)	124 (34.3)	84 (27.5)	123 (35.0)	460 (33.9)	337 (33.5)
	3	54 (15.9)	67 (18.5)	48 (15.7)	62 (17.7)	231 (17.0)	169 (16.8)
	4	26 (7.7)	29 (8.0)	18 (5.9)	25 (7.1)	98 (7.2)	73 (7.2)
	5	5 (1.5)	7 (1.9)	8 (2.6)	6 (1.7)	26 (1.9)	20 (2.0)
	6	2 (0.6)	-	1 (0.3)	-	3 (0.2)	3 (0.3)
CHA2DS2-VASc Score	n (missing)	339 (0)	360 (4)	303 (3)	350 (2)	1352 (9)	1002 (7)
	Mean (SD)	3.4 (1.5)	3.4 (1.5)	3.2 (1.6)	3.3 (1.5)	3.3 (1.5)	3.3 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 8	0 to 8	0 to 8	0 to 8
CHA2DS2-VASc score categories, n(%)	n (missing)	339 (0)	360 (4)	303 (3)	350 (2)	1352 (9)	1002 (7)
	0	2 (0.6)	3 (0.8)	7 (2.3)	4 (1.1)	16 (1.2)	12 (1.2)
	1	32 (9.4)	32 (8.9)	31 (10.2)	32 (9.1)	127 (9.4)	95 (9.5)
	2	76 (22.4)	69 (19.2)	73 (24.1)	85 (24.3)	303 (22.4)	218 (21.8)
	3	77 (22.7)	89 (24.7)	75 (24.8)	69 (19.7)	310 (22.9)	241 (24.1)
	4	80 (23.6)	85 (23.6)	56 (18.5)	83 (23.7)	304 (22.5)	221 (22.1)

**Table 09 : Risk scores**  
**Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=339) (n %)	Cohort 3 (N=364) (n %)	Cohort 4 (N=306) (n %)	Cohort 5 (N=352) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1361)	Total Prospective patients Cohorts 1 to 4 (N=1009)
	5	39 (11.5)	49 (13.6)	35 (11.6)	45 (12.9)	168 (12.4)	123 (12.3)
	6-9	33 (9.7)	33 (9.2)	26 (8.6)	32 (9.1)	124 (9.2)	92 (9.2)
HAS-BLED score	n (missing)	229 (110)	325 (39)	249 (57)	280 (72)	1083 (278)	803 (206)
	Mean (SD)	1.4 (1.0)	1.5 (0.9)	1.3 (1.0)	1.4 (1.0)	1.4 (1.0)	1.4 (1.0)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 5	0 to 4	0 to 5	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	229 (110)	325 (39)	249 (57)	280 (72)	1083 (278)	803 (206)
	0	36 (15.7)	40 (12.3)	54 (21.7)	57 (20.4)	187 (17.3)	130 (16.2)
	1	96 (41.9)	141 (43.4)	111 (44.6)	100 (35.7)	448 (41.4)	348 (43.3)
	2	60 (26.2)	103 (31.7)	50 (20.1)	90 (32.1)	303 (28.0)	213 (26.5)
	3	32 (14.0)	35 (10.8)	31 (12.4)	29 (10.4)	127 (11.7)	98 (12.2)
	4	5 (2.2)	4 (1.2)	3 (1.2)	3 (1.1)	15 (1.4)	12 (1.5)
	5	-	2 (0.6)	-	1 (0.4)	3 (0.3)	2 (0.2)

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : HUNGARY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 2	0	1	50	-	-	-	-	-	-	1	50	-	-	-	-	-	-	-	-
	1	17	53.1	-	-	2	6.3	-	-	1	3.1	2	6.3	7	21.9	3	9.4	-	-
	2	33	44.6	15	20.3	4	5.4	2	2.7	1	1.4	-	-	7	9.5	12	16.2	2	-
	3	37	51.4	8	11.1	1	1.4	2	2.8	6	8.3	1	1.4	6	8.3	11	15.3	5	-
	4	42	52.5	10	12.5	2	2.5	-	-	7	8.8	1	1.3	12	15	6	7.5	-	-
	5	15	41.7	11	30.6	1	2.8	1	2.8	1	2.8	6	16.7	-	-	1	2.8	3	-
6-9	9	27.3	16	48.5	1	3	-	-	-	-	1	3	5	15.2	1	3	-	-	
Cohort 3	0	-	-	-	-	-	-	-	-	-	-	-	-	1	33.3	2	66.7	-	-
	1	13	43.3	2	6.7	-	-	2	6.7	3	10	1	3.3	4	13.3	5	16.7	2	-
	2	30	46.9	11	17.2	1	1.6	-	-	13	20.3	1	1.6	3	4.7	5	7.8	5	-
	3	51	59.3	10	11.6	4	4.7	3	3.5	8	9.3	3	3.5	2	2.3	5	5.8	3	-
	4	36	43.4	22	26.5	6	7.2	3	3.6	3	3.6	1	1.2	4	4.8	8	9.6	2	-
	5	21	46.7	9	20	1	2.2	2	4.4	-	-	-	-	8	17.8	4	8.9	4	-
6-9	12	38.7	10	32.3	1	3.2	-	-	3	9.7	-	-	3	9.7	2	6.5	2	-	
Cohort 4	0	4	57.1	-	-	-	-	1	14.3	-	-	-	-	1	14.3	1	14.3	-	-
	1	17	54.8	-	-	3	9.7	-	-	2	6.5	-	-	4	12.9	5	16.1	-	-
	2	36	50	11	15.3	3	4.2	1	1.4	5	6.9	1	1.4	7	9.7	8	11.1	1	-
	3	52	72.2	12	16.7	1	1.4	-	-	1	1.4	-	-	4	5.6	2	2.8	3	-
	4	36	64.3	10	17.9	5	8.9	-	-	-	-	-	-	2	3.6	3	5.4	-	-
	5	15	42.9	6	17.1	-	-	1	2.9	1	2.9	-	-	9	25.7	3	8.6	-	-
6-9	10	38.5	10	38.5	1	3.8	-	-	-	-	2	7.7	3	11.5	-	-	-	-	
Cohort 5	0	3	75	-	-	1	25	-	-	-	-	-	-	-	-	-	-	-	-
	1	15	46.9	3	9.4	1	3.1	1	3.1	4	12.5	-	-	4	12.5	4	12.5	-	-
	2	54	63.5	6	7.1	3	3.5	-	-	6	7.1	-	-	5	5.9	11	12.9	-	-
	3	40	58	11	15.9	2	2.9	1	1.4	6	8.7	-	-	3	4.3	6	8.7	-	-
	4	43	51.8	20	24.1	3	3.6	-	-	1	1.2	3	3.6	8	9.6	5	6	-	-
	5	28	62.2	5	11.1	4	8.9	2	4.4	-	-	-	-	3	6.7	3	6.7	-	-
6-9	11	34.4	13	40.6	1	3.1	1	3.1	-	-	-	-	6	18.8	-	-	-	-	

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : HUNGARY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	8	50	-	-	1	6.3	1	6.3	1	6.3	-	-	2	12.5	3	18.8	-
	1	62	49.6	5	4	6	4.8	3	2.4	10	8	3	2.4	19	15.2	17	13.6	2
	2	153	51.9	43	14.6	11	3.7	3	1	25	8.5	2	0.7	22	7.5	36	12.2	8
	3	180	60.2	41	13.7	8	2.7	6	2	21	7	4	1.3	15	5	24	8	11
	4	157	52	62	20.5	16	5.3	3	1	11	3.6	5	1.7	26	8.6	22	7.3	2
	5	79	49.1	31	19.3	6	3.7	6	3.7	2	1.2	6	3.7	20	12.4	11	6.8	7
	6-9	42	34.4	49	40.2	4	3.3	1	0.8	3	2.5	3	2.5	17	13.9	3	2.5	2
Total Prospective patients Cohorts 1 to 4	0	5	41.7	-	-	-	-	1	8.3	1	8.3	-	-	2	16.7	3	25	-
	1	47	50.5	2	2.2	5	5.4	2	2.2	6	6.5	3	3.2	15	16.1	13	14	2
	2	99	47.1	37	17.6	8	3.8	3	1.4	19	9	2	1	17	8.1	25	11.9	8
	3	140	60.9	30	13	6	2.6	5	2.2	15	6.5	4	1.7	12	5.2	18	7.8	11
	4	114	52.1	42	19.2	13	5.9	3	1.4	10	4.6	2	0.9	18	8.2	17	7.8	2
	5	51	44	26	22.4	2	1.7	4	3.4	2	1.7	6	5.2	17	14.7	8	6.9	7
	6-9	31	34.4	36	40	3	3.3	-	-	3	3.3	3	3.3	11	12.2	3	3.3	2

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : HUNGARY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
Cohort 2	0	18	51.4	-	-	4	11.4	-	-	4	11.4	-	-	-	-	9	25.7	1
	1	56	60.9	6	6.5	2	2.2	2	2.2	5	5.4	4	4.3	9	9.8	8	8.7	4
	2	25	42.4	17	28.8	1	1.7	-	-	2	3.4	2	3.4	9	15.3	3	5.1	1
	3	3	10	14	46.7	-	-	2	6.7	-	-	5	16.7	6	20	-	-	2
	4-9	-	-	5	100	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 3	0	23	62.2	-	-	2	5.4	-	-	5	13.5	-	-	-	-	7	18.9	3
	1	78	57.4	11	8.1	7	5.1	2	1.5	19	14	1	0.7	7	5.1	11	8.1	5
	2	31	32.3	32	33.3	3	3.1	5	5.2	3	3.1	4	4.2	8	8.3	10	10.4	7
	3	10	29.4	13	38.2	1	2.9	1	2.9	1	2.9	1	2.9	7	20.6	-	-	1
	4-9	1	20	-	-	-	-	1	20	-	-	-	-	2	40	1	20	1
Cohort 4	0	37	69.8	-	-	4	7.5	-	-	4	7.5	-	-	-	-	8	15.1	1
	1	73	65.8	9	8.1	8	7.2	1	0.9	3	2.7	-	-	9	8.1	8	7.2	-
	2	15	31.3	19	39.6	-	-	2	4.2	1	2.1	1	2.1	9	18.8	1	2.1	2
	3	7	22.6	14	45.2	1	3.2	-	-	-	-	-	-	7	22.6	2	6.5	-
	4-9	1	33.3	2	66.7	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 5	0	36	63.2	-	-	6	10.5	-	-	6	10.5	-	-	-	-	9	15.8	-
	1	71	71	4	4	3	3	-	-	7	7	1	1	5	5	9	9	-
	2	34	37.8	30	33.3	4	4.4	2	2.2	-	-	2	2.2	12	13.3	6	6.7	-
	3	4	13.8	11	37.9	1	3.4	3	10.3	1	3.4	-	-	8	27.6	1	3.4	-
	4-9	1	25	2	50	-	-	-	-	-	-	-	-	1	25	-	-	-
Total Prospective patients Cohorts 1 to 5	0	114	62.6	-	-	16	8.8	-	-	19	10.4	-	-	-	-	33	18.1	5
	1	278	63.3	30	6.8	20	4.6	5	1.1	34	7.7	6	1.4	30	6.8	36	8.2	9
	2	105	35.8	98	33.4	8	2.7	9	3.1	6	2	9	3.1	38	13	20	6.8	10
	3	24	19.4	52	41.9	3	2.4	6	4.8	2	1.6	6	4.8	28	22.6	3	2.4	3

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : HUNGARY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
	4-9	3	17.6	9	52.9	-	-	1	5.9	-	-	-	-	3	17.6	1	5.9	1
Total Prospective patients Cohorts 1 to 4	0	78	62.4	-	-	10	8	-	-	13	10.4	-	-	-	-	24	19.2	5
	1	207	61.1	26	7.7	17	5	5	1.5	27	8	5	1.5	25	7.4	27	8	9
	2	71	35	68	33.5	4	2	7	3.4	6	3	7	3.4	26	12.8	14	6.9	10
	3	20	21.1	41	43.2	2	2.1	3	3.2	1	1.1	6	6.3	20	21.1	2	2.1	3
	4-9	2	15.4	7	53.8	-	-	1	7.7	-	-	-	-	2	15.4	1	7.7	1

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

Variable	Statistics	Cohort 2 (N=214) (n %)	Cohort 3 (N=231) (n %)	Cohort 4 (N=222) (n %)	Total Prospective patients Cohorts 1 to 4 (N=667)
TTR value, n(%)	n (missing)	125 (89)	160 (71)	139 (83)	424 (243)
	<65	91 (72.8)	107 (66.9)	99 (71.2)	297 (70.0)
	>=65	34 (27.2)	53 (33.1)	40 (28.8)	127 (30.0)
TTR	n (missing)	125 (89)	160 (71)	139 (83)	424 (243)
	Mean (SD)	50.2 (25.6)	51.3 (24.9)	50.8 (25.3)	50.8 (25.2)
	Median (IQR)	52.3 (33.6 to 67.1)	50.8 (34.1 to 70.0)	54.7 (31.8 to 70.6)	52.6 (33.6 to 69.0)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	1257	1758	1481	4496
	2-3	526 (41.8)	764 (43.5)	631 (42.6)	1921 (42.7)
	<2	510 (40.6)	692 (39.4)	566 (38.2)	1768 (39.3)
	>3	221 (17.6)	302 (17.2)	284 (19.2)	807 (17.9)
INR	n	1257	1758	1481	4496
	Mean (SD)	2.3 (0.9)	2.3 (1.0)	2.3 (1.0)	2.3 (0.9)
	Median (IQR)	2.1 (1.7 to 2.7)	2.2 (1.7 to 2.7)	2.2 (1.7 to 2.8)	2.2 (1.7 to 2.8)
	Min to Max	0.9 to 10.2	0.9 to 10.7	0.9 to 13.9	0.9 to 13.9



**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1009	55	5.72	(4.40 to 7.46)
	<b>Cardiovascular death</b>	1009	27	2.81	(1.93 to 4.10)
	<b>Non-Cardiovascular death</b>	1009	21	2.19	(1.43 to 3.35)
	<b>Undetermined cause</b>	1009	7	0.73	(0.35 to 1.53)
Stroke/SE		1009	14	1.47	(0.87 to 2.47)
Major bleed		1009	14	1.47	(0.87 to 2.48)
Acute coronary syndrome		1009	7	0.73	(0.35 to 1.53)
Congestive Heart Failure		1009	19	2.00	(1.27 to 3.13)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

		HUNGARY		
Outcome	Cause	N	Events	%
<b>Cardiovascular causes</b>	Myocardial infarction	27	1	3.70
	Ischaemic stroke	27	1	3.70
	Congestive heart failure	27	14	51.85
	Sudden or unwitnessed death	27	2	7.41
	Other	27	9	33.33
<b>Non-cardiovascular causes</b>	Accidental / trauma	21	1	4.76
	Respiratory failure	21	4	19.05
	Infection/sepsis	21	3	14.29
	Malignancy	21	9	42.86
	Other	21	4	19.05

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :HUNGARY**

OUTCOME	HUNGARY		
	N	Events	%
Stroke(not including systemic embolism)	1009	13	1.29
Primary Ischemic Stroke	1009	7	0.69
<b>Primary intracerebral hemorrhage*</b>	1009	4	0.40
<i>Intracerebral</i>	1009	1	0.10
<i>Subarachnoid</i>	1009	2	0.20
Undetermined	1009	2	0.20

\*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	12	11.83	0	-	-
1	95	90.69	2	2.21	(0.55 to 8.82)
2	218	208.31	8	3.84	(1.92 to 7.68)
3	241	232.66	9	3.87	(2.01 to 7.44)
4+	436	410.85	35	8.52	(6.12 to 11.87)
Unknown	7	6.45	1	15.51	(2.19 to 110.10)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	12	11.83	0	-	-
1	95	90.69	1	1.10	(0.16 to 7.83)
2	218	206.64	5	2.42	(1.01 to 5.81)
3	241	232.62	1	0.43	(0.06 to 3.05)
4+	436	407.71	7	1.72	(0.82 to 3.60)
Unknown	7	6.45	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : HUNGARY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	12	11.83	0	-	-
1	95	89.83	2	2.23	(0.56 to 8.90)
2	218	206.08	3	1.46	(0.47 to 4.51)
3	241	230.81	4	1.73	(0.65 to 4.62)
4+	436	408.70	5	1.22	(0.51 to 2.94)
Unknown	7	6.45	0	-	-